Skip to main content

Lupus

    Avacopan is as effective as steroids in ANCA Assoc Vasculitis – 330 pt RCT AAV Rx w/ RTX or CTX but randomized to pred
    3 years 10 months ago
    Avacopan is as effective as steroids in ANCA Assoc Vasculitis – 330 pt RCT AAV Rx w/ RTX or CTX but randomized to prednisone or avacopan (C5aR antagonist). Avacopan=prednisone remission rates same (72% vs 70%) wk 26 & wk 52 (66% vs 55%). #EULAR2020 #OP0011 https://t.co/WIXJCYkxSb
    RT @KDAO2011: #EULAR2020 OP0096 Dr. L Chatzis study on Sjogren:
    1. 2nd most common autoimm dz in women
    2. women:men rat
    3 years 10 months ago
    #EULAR2020 OP0096 Dr. L Chatzis study on Sjogren: 1. 2nd most common autoimm dz in women 2. women:men ratio 20:1 (not 9:1) 3. 2 types Ro-Ab: nuc. Ro60 (assc w/La)and cytopls. Ro52 (assc w/ILD/myositis) 4. Seroneg. Sjogren's (neg Ro/La/RF) good prognosis:⬇️lymphoma @RheumNow https://t.co/fV3ltQqnkf
    RT @Janetbirdope: NPSLE is more than a headache! probs with dx, uncertain Rx, overlap with common probs - infection, pai
    3 years 10 months ago
    NPSLE is more than a headache! probs with dx, uncertain Rx, overlap with common probs - infection, pain, fibromyalgia, drug side effects, etc. Spectrum in NPSLE just like SLE has a spectrum of cutaneous findings T Huizanga discusses @eular_org #EULAR2020 @RheumNow @CRASCRRheum https://t.co/sdw0xavWBq
    RT @Janetbirdope: When making a dx of neuropsychiatric SLE I order labs AND @RheumNow @eular_org @CRASCRRheum @earlyarth
    3 years 10 months ago
    When making a dx of neuropsychiatric SLE I order labs AND @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020
    RT @drdavidliew: MTX in GCA (+/- TCZ): can GiACTA data provide insights?

    MTX didn't add anything from data provided, bu
    3 years 10 months ago
    MTX in GCA (+/- TCZ): can GiACTA data provide insights? MTX didn't add anything from data provided, but channelling bias a definite issue (note PNL numerically higher in non-MTX). MTX as adjunct/cover post-TCZ? We'll need to test for it properly FRI0220 #EULAR2020 @RheumNow https://t.co/BCsEKqqaMh
    RT @drdavidliew: I've heard people say FDG uptake on PET/CT in PMR/GCA is just a correlate of systemic inflamm.

    Look at
    3 years 10 months ago
    I've heard people say FDG uptake on PET/CT in PMR/GCA is just a correlate of systemic inflamm. Look at the uptake intensity (SUVmax) vs inflamm markers in n=65 PET/CT in GCA. There's no pattern whatsoever. Not just an expensive ESR! @FreemanHospital SAT0272 #EULAR2020 @RheumNow https://t.co/D4xAZC7KmO
    RT @drdavidliew: To truly address adherence, you need to understand what is impairing it, and tailor an approach to over
    3 years 10 months ago
    To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers. Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes! EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV
    RT @drdavidliew: Is there subclinical GCA in PMR pts?

    50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular u
    3 years 10 months ago
    Is there subclinical GCA in PMR pts? 50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular uptake, of which 10 had no GCA symptoms at all. Is PMR sometimes just the tip of the GCA iceberg? Do the aSx USS+ pts get GCA Sx eventually? Bonn SAT0254 #EULAR2020 @RheumNow https://t.co/UmsixY29Qh
    RT @drdavidliew: GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comp
    3 years 10 months ago
    GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail. Large Israeli database says there are links (EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why? OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah
    RT @KDAO2011: #EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted
    3 years 10 months ago
    #EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs